Volume 27, Number 11—November 2021
Research Letter
Online Registry of COVID-19–Associated Mucormycosis Cases, India, 2021
Table
Characteristic | No. (%) |
---|---|
Total |
65 (100) |
Sex | |
M | 48 (74) |
F |
17 (26) |
Underlying conditions | |
Diabetes mellitus | 52 (80) |
Hypertension | 13 (20) |
Chronic corticosteroid use | 2 (3) |
Asthma/COPD |
1 (1.5) |
Hospitalized† | 54 (84) |
Intensive care unit‡ | 15 (28) |
Required surgical intervention |
26 (40) |
Site of infection | |
Sinus | 60 (92) |
Eye | 34 (52) |
Cerebral | 5 (7.7) |
Gastrointestinal | 5 (7.7) |
Skin | 1 (1.5) |
Pulmonary |
0 |
Treatment | |
Steroids | 53 (82) |
Methylprednisolone | 32 (49) |
Dexamethasone | 18 (28) |
Prednisone | 5 (8) |
Budesonide | 6 (9) |
Steroids >10 d§ | 28 (61) |
Antifungal medication | |
Posaconazole | 43 (66) |
Isavuconazole | 3 (5) |
Amphotericin B | 60 (92) |
Liposomal | 54 (83) |
Deoxycholate | 14 (22) |
Lipid complex | 8 (12) |
Antiviral medication | |
Remdesivir | 31 (48) |
Favipravir | 18 (28) |
Zinc supplementation | 36 (55) |
Other antimicrobial chemotherapy | |
Doxycycline | 30 (46) |
Azithromycin | 25 (38) |
Ivermectin |
25 (38) |
No. vaccine doses | |
0 | 56 (86) |
1 | 7 (11) |
2 | 2 (3) |
*Totals might exceed 100% when >1 category applies. COPD, chronic obstructive pulmonary disease. †Data available for 64 patients. ‡Data available for 54 patients. §Data available for 46 patients.
Page created: August 13, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.